Article
Comparison of two commercial assays for the characterization of rpoB mutations in Mycobacterium tuberculosis and description of new mutations conferring weak resistance to rifampicin.
The Journal of antimicrobial chemotherapy - 1 Aug 2009
Hauck Yolande, Fabre Michel, Vergnaud Gilles, Soler Charles, Pourcel Christine
Abstract excerpt
OBJECTIVES: The aim of this study was to compare the efficiency of two commercial assays, INNO-LiPA Rif.TB and MTBDRplus, for the identification of mutations in the rpoB hot-spot region and to assess the efficiency of these mutations in conferring resistance to rifampicin. METHODS: A collection of 126 rifampicin-resistant Mycobacterium tuberculosis and Mycobacterium africanum isolates and 18...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.